Interleukin-17FT7488 allele is associated with a decreased risk of colorectal cancer and tumor progression

Gene

Volumn 561, Issue 1, 2015, Pages 88-94

  Nemati, Kazem ^a   Golmoghaddam, Hossein ^a   Hosseini, Seyed Vahid ^b   Ghaderi, Abbas ^a,c   Doroudchi, Mehrnoosh ^a,c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colorectal cancer; Haplotype; IL 17A; IL 17F; IL 23R; Single nucleotide polymorphisms

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 23 RECEPTOR; IL17A PROTEIN, HUMAN; IL17F PROTEIN, HUMAN; IL23R PROTEIN, HUMAN; INTERLEUKIN RECEPTOR;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH; TUMOR VOLUME; BLOOD; COLORECTAL NEOPLASMS; DISEASE COURSE; DNA SEQUENCE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY;

BASE SEQUENCE; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN; SEQUENCE ANALYSIS, DNA;

EID: 84924624351     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.02.014     Document Type: Article

References (46)

1. Alfassi Z.B., Boger Z., Ronen Y. Statistical Treatment of Analytical Data, Boca Raton (FL) 2005, CRC Press.
2. Arisawa T., Tahara T., Shibata T., Nagasaka M., Nakamura M., Kamiya Y., Fujita H., Nakamura M., Yoshioka D., Arima Y. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J. Clin. Immunol. 2008, 28:44-49.
3. Bernstein C.N., Blanchard J.F., Kliewer E., Wajda A. Cancer risk in patients with inflammatory bowel disease. Cancer 2001, 91:854-862.
4. Büning C., Schmidt H.J., Molnar T., De Jong D., Fiedler T., Bühner S., Sturm A., Baumgart D., Nagy F., Lonovics J. Heterozygosity for IL23R p. Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis. Aliment. Pharmacol. Ther. 2007, 26:1025-1033.
5. Capon F., Di Meglio P., Szaub J., Prescott N.J., Dunster C., Baumber L., Timms K., Gutin A., Abkevic V., Burden A.D. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 2007, 122:201-206.
6. Chen B., Zeng Z., Hou J., Chen M., Gao X., Hu P. Association of interleukin-17F 7488 single nucleotide polymorphism and inflammatory bowel disease in the Chinese population. Scand. J. Gastroenterol. 2009, 44:720-726.
7. Chen X., Wan J., Liu J., Xie W., Diao X., Xu J., Zhu B., Chen Z. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010, 69:348-354.
8. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 2008, 8:337-348.
9. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., Steinhart A.H., Abraham C., Regueiro M., Griffiths A. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
10. Espinoza J.L., Takami A., Nakata K., Onizuka M., Kawase T., Akiyama H., Miyamura K., Morishima Y., Fukuda T., Kodera Y. A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS One 2011, 6:e26229.
11. Farjadian S., Ghaderi A. HLA class II genetic diversity in Arabs and Jews of Iran. Iran. J. Immunol. 2007, 4:85-93.
12. Farjadian S., Naruse T., Kawata H., Ghaderi A., Bahram S., Inoko H. Molecular analysis of HLA allele frequencies and haplotypes in Baloch of Iran compared with related populations of Pakistan. Tissue Antigens 2004, 64:581-587.
13. Fridman W.H., Galon J., Pagès F., Tartour E., Sautès-Fridman C., Kroemer G. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res. 2011, 71:5601-5605.
14. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
15. Glas J., Seiderer J., Wetzke M., Konrad A., Török H.-P., Schmechel S., Tonenchi L., Grassl C., Dambacher J., Pfennig S. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS One 2007, 2:e819.
16. Howell W.M., Rose-Zerilli M.J. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J. Nutr. 2007, 137:194S-199S.
17. Itzkowitz S.H., Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G7-G17.
18. James K., Eisenhauer E., Christian M., Terenziani M., Vena D., Muldal A., Therasse P. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J. Natl. Cancer Inst. 1999, 91:523-528.
19. Karaderi T., Harvey D., Farrar C., Appleton L.H., Stone M.A., Sturrock R.D., Brown M.A., Wordsworth P., Pointon J.J. Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series. Rheumatology (Oxford) 2009, 48:386-389.
20. Kawaguchi M., Takahashi D., Hizawa N., Suzuki S., Matsukura S., Kokubu F., Maeda Y., Fukui Y., Konno S., Huang S.-K. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J. Allergy Clin. Immunol. 2006, 117:795-801.
21. Kolls J.K., Lindén A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476.
22. Lan F., Zhang L., Wu J., Zhang J., Zhang S., Li K., Qi Y., Lin P. IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma. Int. J. Colorectal Dis. 2011, 26:1511-1518.
23. Liang S.C., Long A.J., Bennett F., Whitters M.J., Karim R., Collins M., Goldman S.J., Dunussi-Joannopoulos K., Williams C.M., Wright J.F. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J. Immunol. 2007, 179:7791-7799.
24. Liu X.K., Lin X., Gaffen S.L. Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. J. Biol. Chem. 2004, 279:52762-52771.
25. Ma M., Jin G.J., Yun K., Mu R.Q., Zhao M., Yu X.O., Wang S., Shang H. Correlation of IL-1F genetic polymorphisms with the risk of colorectal cancer among Chinese populations. Tumour Biol. 2014, 10.1007/s13277-014-2653-y.
26. McKenzie B.S., Kastelein R.A., Cua D.J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006, 27:17-23.
27. Merlo L.M., Maley C.C. The role of genetic diversity in cancer. J. Clin. Invest. 2010, 120:401-403.
28. Monteleone G., Pallone F., Stolfi C. The dual role of inflammation in colon carcinogenesis. Int. J. Mol. Sci. 2012, 13:11071-11084.
29. Moseley T., Haudenschild D., Rose L., Reddi A. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003, 14:155-174.
30. Omrane I., Marrakchi R., Baroudi O., Mezlini A., Ayari H., Medimegh I., Stambouli N., Kourda N., Bouzaienne H., Uhrhammer N., Bougatef K., Bignon Y.J., Benammar-Elgaaied A. Significant association between interleukin-17A polymorphism and colorectal cancer. Tumour Biol. 2014, 35:6627-6632.
31. Poole E.M., Curtin K., Hsu L., Kulmacz R.J., Duggan D.J., Makar K.W., Xiao L., Carlson C.S., Slattery M.L., Caan B.J. Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer. Int. J. Mol. Epidemiol. Genet. 2011, 2:300.
32. Radosavljevic G., Ljujic B., Jovanovic I., Srzentic Z., Pavlovic S., Zdravkovic N., Milovanovic M., Bankovic D., Knezevic M., Acimovic L. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 2009, 57:135-144.
33. Rouvier E., Luciani M., Mattei M., Denizot F., Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 1993, 150:5445-5456.
34. Rudensky A.Y., Campbell D.J. In vivo sites and cellular mechanisms of T reg cell-mediated suppression. J. Exp. Med. 2006, 203:489-492.
35. Safrany E., Pazar B., Csöngei V., Jaromi L., Polgar N., Sipeky C., Horvath I., Zeher M., Poór G., Melegh B. Variants of the IL23R gene are associated with ankylosing spondylitis but not with Sjögren syndrome in Hungarian population samples. Scand. J. Immunol. 2009, 70:68-74.
36. Sandler R.S., Halabi S., Baron J.A., Budinger S., Paskett E., Keresztes R., Petrelli N., Pipas J.M., Karp D.D., Loprinzi C.L. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 2003, 348:883-890.
37. Shi Y., Lin H., Cui J., Qi H., Florholmen J., Liu Z., Cui G. The role of interleukin-17A in colorectal tumorigenesis. Cancer Biother. Radiopharm. 2013, 28:429-432.
38. Southam L., Heath O., Chapman K., Loughlin J. Association analysis of the interleukin 17 genes IL17A and IL17F as potential osteoarthritis susceptibility loci. Ann. Rheum. Dis. 2006, 65:556-557.
39. Tong Z., Yang X.O., Yan H., Liu W., Niu X., Shi Y., Fang W., Xiong B., Wan Y., Dong C. A protective role by interleukin-17F in colon tumorigenesis. PLoS One 2012, 7:e34959.
40. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 2009, 206:1457-1464.
41. Wrobel T., Gebura K., Wysoczanska B., Jazwiec B., Dobrzynska O., Mazur G., Kuliczkowski K., Bogunia-Kubik K. IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia. J. Cancer Res. Clin. Oncol. 2014, 140:1551-1555.
42. Wu S., Rhee K.-J., Albesiano E., Rabizadeh S., Wu X., Yen H.-R., Huso D.L., Brancati F.L., Wick E., McAllister F. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17T cell responses. Nat. Med. 2009, 15:1016-1022.
43. Wu X., Zeng Z., Chen B., Yu J., Xue L., Hao Y., Chen M., Sung J.J., Hu P. Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int. J. Cancer 2010, 127:86-92.
44. Xie Y., Sheng W., Xiang J., Ye Z., Yang J. Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis. Cancer Invest. 2010, 28:598-607.
45. Yang L., Anderson D.E., Baecher-Allan C., Hastings W.D., Bettelli E., Oukka M., Kuchroo V.K., Hafler D.A. IL-21 and TGF-&bgr; are required for differentiation of human TH17 cells. Nature 2008, 454:350-352.
46. Zhang Y., Ma D., Zhang Y., Tian Y., Wang X., Qiao Y., Cui B. The imbalance of Th17/Treg in patients with uterine cervical cancer. Clin. Chim. Acta 2011, 412:894-900.